Euroscreen Announces the Completion of Research Agreement with GNF and Novartis

Euroscreen and GNF will be engaged in research focused upon the development of therapeutic antibodies targeting G protein coupled receptors (GPCRs). Financial details of the agreement, and the specific GPCRs involved were not disclosed.

Brussels, Belgium (PRWEB) March 23, 2007 -- Euroscreen and GNF will be engaged in research focused upon the development of therapeutic antibodies targeting G protein coupled receptors (GPCRs). Financial details of the agreement, and the specific GPCRs involved were not disclosed. Commenting on the new research collaboration, Dr. Jean Combalbert, Euroscreen's CEO indicated, "Euroscreen has years of success in soliciting anti-GPCR antibodies, and more specifically, anti-GPCR antibodies with agonist or antagonist activities. This new deal is again demonstrating our great interest to anti-GPCR antibodies collaborations to develop therapeutic antibodies against relevant targets."

Combalbert continues, "Therapeutic antibodies are well recognized to provide excellent efficacy and rapid development time frames. This agreement with GNF and Novartis is a logical extension of our own strategy to develop new therapeutics for unmet medical needs. Both partners are combining their expertise and making commitments of resources to the collaboration."

About Euroscreen s.a. - www.euroscreen.com
Euroscreen is a preclinical-stage biopharmaceutical company focusing on the discovery, development and partnering of therapeutics for unmet medical needs. Euroscreen has developed a pipeline of compounds targeting G protein-coupled receptors (GPCRs) using over 12 years of experience in research and commercialization of this critical class of drug targets in association with the University of Brussels. Euroscreen uses the AequoScreen™ cellular assay platform extensively in its screening of GPCRs for candidate drugs and then optimizes and patents specific drug candidates for preclinical development.
The Company has developed a broad GPCR patent portfolio for licensing to biopharmaceutical companies. Such patents address targets such as CCR5, Chemerin receptor, GPR43, GPR7/8, FPRL2, purinergic receptors (P2Y4, P2Y11 and P2Y13) and SHIP2 for type II diabetes. Euroscreen is able to offer intellectual property rights to companies for the development of therapeutic drugs that act through the above-mentioned targets.
Euroscreen has a dual platform strategy of combining its drug discovery activities with its services business unit to provide biopharmaceutical companies around the world with exceptional GPCR testing. The company has research and licensing partnerships with Alchemia, Cephalon, ChemDiv, GNF, HGS, ICOS, Medarex, Novartis and Pfizer Inc. Euroscreen is a privately held company based in Brussels, Belgium.

###